


## Ozagrel hydrochloride

### Chemical Properties

CAS No. : 78712-43-3  
 Formula: C<sub>13</sub>H<sub>12</sub>N<sub>2</sub>O<sub>2</sub>·HCl  
 Molecular Weight: 264.71  
 Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year  
*Actual storage temperature shall be subject to the COA.*



### Biological Description

Description	Ozagrel hydrochloride (OKY-046 HCl) is a selective thromboxane A <sub>2</sub> synthetase inhibitor used for the improvement of postoperative cerebrovascular contraction and accompanying cerebral ischaemia.
Targets(IC50)	Prostaglandin Receptor,Thrombin
In vitro	Administration of 3 mg/kg Ozagrel significantly reduces the area and volume of cortical infarcts in rats following cerebral middle artery occlusion and reperfusion. Ozagrel also inhibits neural deficits in a rat model of microthrombosis and enhances deteriorated spontaneous motor activity and motor coordination in a conscious mouse model of cerebral ischemia-reperfusion. Furthermore, Ozagrel prevents the increase in lactate dehydrogenase activity in guinea pig pulmonary lavage fluid and blocks the production of thromboxane A <sub>2</sub> induced by oleic acid in guinea pigs, subsequently reducing the total protein concentration and the numbers of macrophages and neutrophils, as well as the expression of monocyte chemoattractant protein-1 and interleukin-8 mRNA in the entire lung. In cats, Ozagrel inhibits the reduction of brain tissue-specific gravity induced by reperfusion in the SHR model of cerebral ischemia-reperfusion and restores the decreased cortical PO <sub>2</sub> post-ischemia upon reperfusion. Ozagrel also increases the level of 6-keto-PGF(1α), a metabolite of prostacyclin I <sub>2</sub> (PGI <sub>2</sub> ), in the brain tissue following ischemia-reperfusion.

### Solubility Information

Solubility	DMSO: 65 mg/mL (245.55 mM),Sonication is recommended. H <sub>2</sub> O: 48 mg/mL (181.33 mM),Sonication is recommended. Ethanol: 6 mg/mL (22.67 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.56 mM),Sonication is recommended. <i>Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.</i>

### Preparing Stock Solutions

---

	1mg	5mg	10mg
1 mM	3.7777 mL	18.8886 mL	37.7772 mL
5 mM	0.7555 mL	3.7777 mL	7.5554 mL
10 mM	0.3778 mL	1.8889 mL	3.7777 mL
50 mM	0.0756 mL	0.3778 mL	0.7555 mL

---

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

### Reference

- Ishitsuka Y, et al. *J Pharmacol Sci*, 2009, 111(2), 211-215.
- Imamura T, et al. *Arzneimittelforschung*, 2003, 53(10), 688-694.
- Ichikawa K, et al. *Pharmacology*, 1999, 59(5), 257-265.
- Ishitsuka Y, et al. *J Pharm Pharmacol*, 2004, 56(4), 513-520.
- Naito J, et al. *Eur J Pharmacol*. 1983, 91(1), 41-48.

**Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins**

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use

Tel:781-999-4286 E\_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481